Meningococcal disease: Changes in epidemiology and prevention

Clinical Epidemiology

Volumn 4, Issue 1, 2012, Pages 237-245

  Chang, Qiuzhi ^a   Tzeng, Yih Ling ^b   Stephens, David S ^a,b,c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Veterans   (United States)

Author keywords

Conjugate vaccines; Meningococcal disease; Meningococcal vaccines; Neisseria meningitidis

Indexed keywords

MENINGOCOCCUS VACCINE;

BLOOD GROUP TYPING; DEVELOPED COUNTRY; DISEASE TRANSMISSION; EUROPE; GENOTYPE; HERD IMMUNITY; HUMAN; INCIDENCE; MENINGOCOCCEMIA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; OUTER MEMBRANE; PACIFIC ISLANDS; PATHOPHYSIOLOGY; POPULATION DENSITY; PREDICTION; PROPHYLAXIS; REVIEW; WESTERN HEMISPHERE;

EID: 84866713386     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S28410     Document Type: Review

References (102)

1. Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1-20.
2. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378-1388.
3. Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population, 1963-1998: database study. BMJ. 2003; 327(7415):596-597.
4. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9): 1267-1284.
5. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1-21.
6. Oster P, Lennon D, O'Hallahan J, et al. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005; 23(17-18):2191-2196.
7. Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz. 1999;94(4):433-440.
8. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol. 2009;38(2):413-418.
9. Brehony C, Jolley KA, Maiden MC. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev. 2007;31(1):15-26.
10. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27 Suppl 2:B51-B63.
11. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180(6):1894-1901.
12. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191.
13. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50 Suppl 2:S37-S44.
14. Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J Infect Dis. 2010;201(8):1208-1224.
15. Caugant DA, Nicolas P. Molecular surveillance of meningococcal meningitis in Africa. Vaccine. 2007;25 Suppl 1:A8-A11.
16. Molesworth AM, Cuevas LE, Connor SJ, Morse AP, Thomson MC. Environmental risk and meningitis epidemics in Africa. Emerg Infect Dis. 2003;9(10):1287-1293.
17. Greenwood BM, Bradley AK, Wall RA. Meningococcal disease and season in sub-Saharan Africa. Lancet. 1985;2(8459):829-830.
18. Sultan B, Labadi K, Guegan JF, Janicot S. Climate drives the meningitis epidemics onset in west Africa. PLoS Med. 2005;2(1):e6.
19. Diermayer M, Hedberg K, Hoesly F, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA. 1999;281(16):1493-1497.
20. Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis. 2010;10:175.
21. Swartley JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A. 1997;94(1): 271-276.
22. Troy FA 2nd. Polysialylation: from bacteria to brains. Glycobiology. 1992;2(1):5-23.
23. Sotolongo F, Campa C, Casanueva V, et al. Cuban meningococcal BC vaccine: experiences and contributions from 20 years of application. MEDICC Rev. 2008;9(1):16-22.
24. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340(8827):1074-1078.
25. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 1994;62(10): 4419-4424.
26. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol. 1995;24(5):1050-1057.
27. Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(8): 597-607.
28. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816): 617-624.
29. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012; 307(6):573-582.
30. Cohn AC, Messonnier NE. Inching toward a serogroup B meningococcal vaccine for infants. JAMA. 2012;307(6):614-615.
31. Stephens DS. Prevention of serogroup B meningococcal disease. Lancet. 2012;379(9816):592-594.
32. Control ECfDPa. Annual epidemiological report 2011-Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Euro Surveill. 2011;16(45):20012.
33. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ. 1993;42(2):21-30.
34. Kellerman SE, McCombs K, Ray M, et al. Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper-and hyposporadic rates of meningococcal disease. J Infect Dis. 2002; 186(1):40-48.
35. Clark TA, Stern E, Pondo T, et al. The effect of quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine on serogroup-specific carriage of Neisseria meningitidis. Presented at the 16th International Pathogenic Neissera conference, Rotterdam, The Netherlands, September 7-12, 2008.
36. Abad R, Agudelo CI, Brandileone MC, et al. Molecular characterization of invasive serogroup Y Neisseria meningitidis strains isolated in the Latin America region. J Infect. 2009;59(2):104-114.
37. Whitney AM, Coulson GB, von Gottberg A, et al. Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol. 2009;47(9):2787-2793.
38. Tsang RS, Henderson AM, Cameron ML, et al. Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003in Canada. J Clin Microbiol. 2007;45(6): 1753-1758.
39. Materu S, Cox HS, Isaakidis P, et al. Serogroup X in meningococcal disease, Western Kenya. Emerg Infect Dis. 2007;13(6):944-945.
40. Gagneux S, Wirth T, Hodgson A, et al. Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis. 2002;8(5):462-466.
41. Gagneux SP, Hodgson A, Smith TA, et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis. 2002;185(5):618-626.
42. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006in Niger. Clin Infect Dis. 2007;44(5):657-663.
43. Delrieu I, Yaro S, Tamekloe TA, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One. 2011;6(5):e19513.
44. Aguilera JF, Perrocheau A, Meffre C, Hahne S, Group WW. Outbreak of serogroup W135meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8(8):761-767.
45. Raghunathan PL, Jones JD, Tiendrebeogo SR, et al. Predictors of immunity after a major serogroup W-135meningococcal disease epidemic, Burkina Faso, 2002. J Infect Dis. 2006;193(5):607-616.
46. Mayer LW, Reeves MW, Al-Hamdan N, et al. Outbreak of W135meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis. 2002;185(11):1596-1605.
47. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580): 2196-2210.
48. Liu TY, Gotschlich EC, Dunne FT, Jonssen EK. Studies on the meningococcal polysaccharides. II. Composition and chemical properties of the group B and group C polysaccharide. J Biol Chem. 1971;246(15): 4703-4712.
49. Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith IC. Structural determination of the polysaccharide antigens of Neisseria meningitidis serogroups Y, W-135, and BO1. Can J Biochem. 1976; 54(1):1-8.
50. Liu TY, Gotschlich EC, Jonssen EK, Wysocki JR. Studies on the meningococcal polysaccharides. I. Composition and chemical properties of the group A polysaccharide. J Biol Chem. 1971;246(9):2849-2858.
51. Bundle DR, Jennings HJ, Kenny CP. Studies on the group-specific polysaccharide of Neisseria meningitidis serogroup X and an improved procedure for its isolation. J Biol Chem. 1974;249(15):4797-4801.
52. Davidsen T, Tonjum T. Meningococcal genome dynamics. Nat Rev Microbiol. 2006;4(1):11-22.
53. Hill DJ, Griffiths NJ, Borodina E, Virji M. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci (Lond). 2010;118(9):547-564.
54. Kriz P, Giorgini D, Musilek M, Larribe M, Taha MK. Microevolution through DNA exchange among strains of Neisseria meningitidis isolated during an outbreak in the Czech Republic. Res Microbiol. 1999;150(4): 273-280.
55. van der Ende A, Hopman CT, Dankert J. Deletion of porA by recombination between clusters of repetitive extragenic palindromic sequences in Neisseria meningitidis. Infect Immun. 1999;67(6): 2928-2934.
56. Berrington AW, Tan YC, Srikhanta Y, et al. Phase variation in meningococcal lipooligosaccharide biosynthesis genes. FEMS Immunol Med Microbiol. 2002;34(4):267-275.
57. Hammerschmidt S, Muller A, Sillmann H, et al. Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol. 1996;20(6): 1211-1220.
58. Hammerschmidt S, Hilse R, van Putten JP, et al. Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J. 1996;15(1):192-198.
59. Cahoon LA, Seifert HS. Focusing homologous recombination: pilin antigenic variation in the pathogenic Neisseria. Mol Microbiol. 2011; 81(5):1136-1143.
60. Helm RA, Seifert HS. Frequency and rate of pilin antigenic variation of Neisseria meningitidis. J Bacteriol. 2010;192(14):3822-3823.
61. Andrews TD, Gojobori T. Strong positive selection and recombination drive the antigenic variation of the PilE protein of the human pathogen Neisseria meningitidis. Genetics. 2004;166(1):25-32.
62. Budroni S, Siena E, Hotopp JC, et al. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A. 2011;108(11): 4494-4499.
63. Tzeng YL, Datta A, Ambrose KD, et al. The MisR/MisS two-component regulatory system influences inner core structure and immunotype of lipooligosaccharide in Neisseria meningitidis. J Biol Chem. 2004;279: 35053-35062.
64. Alcala B, Arreaza L, Salcedo C, et al. Capsule switching among C:2b:P1.2,5meningococcal epidemic strains after mass immunization campaign, Spain. Emerg Infect Dis. 2002;8(12):1512-1514.
65. Simoes MJ, Cunha M, Almeida F, Furtado C, Brum L. Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002-2006. Epidemiol Infect. 2009;137(2):161-165.
66. Stefanelli P, Fazio C, Neri A, Sofia T, Mastrantonio P. First report of capsule replacement among electrophoretic type 37 Neisseria meningitidis strains in Italy. J Clin Microbiol. 2003;41(12):5783-5786.
67. Kertesz DA, Coulthart MB, Ryan JA, Johnson WM, Ashton FE. Serogroup B, electrophoretic type 15 Neisseria meningitidis in Canada. J Infect Dis. 1998;177(6):1754-1757.
68. Tsang RS, Law DK, Tyler SD, et al. Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada. Can J Infect Dis Med Microbiol. 2005;16(3):171-174.
69. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51(9):717-722.
70. Stephens DS. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet. 1999;353(9157):941-942.
71. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969; 129(6):1307-1326.
72. Bishof NA, Welch TR, Beischel LS. C4B deficiency: a risk factor for bacteremia with encapsulated organisms. J Infect Dis. 1990;162(1): 248-250.
73. Hogasen K, Michaelsen T, Mellbye OJ, Bjune G. Low prevalence of complement deficiencies among patients with meningococcal disease in Norway. Scand J Immunol. 1993;37(4):487-489.
74. Westendorp RG, Langermans JA, de Bel CE, et al. Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis. 1995;171(4): 1057-1060.
75. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996;174(4):878-880.
76. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349(9046):170-173.
77. Vermont CL, de Groot R, Hazelzet JA. Bench-to-bedside review: genetic influences on meningococcal disease. Crit Care. 2002;6(1):60-65.
78. Haralambous E, Dolly SO, Hibberd ML, et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis. 2006; 38(9):764-771.
79. Haneberg B, Tonjum T, Rodahl K, Gedde-Dahl TW. Factors preceding the onset of meningococcal disease, with special emphasis on passive smoking, symptoms of ill health. NIPH Ann. 1983;6(2):169-173.
80. Coen PG, Tully J, Stuart JM, et al. Is it exposure to cigarette smoke or to smokers which increases the risk of meningococcal disease in teenagers? Int J Epidemiol. 2006;35(2):330-336.
81. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16(10):979-983.
82. Yusuf HR, Rochat RW, Baughman WS, et al. Maternal cigarette smoking and invasive meningococcal disease: a cohort study among young children in metropolitan Atlanta, 1989-1996. Am J Public Health. 1999;89(5):712-717.
83. Cartwright KA, Jones DM, Smith AJ, et al. Influenza A and meningococcal disease. Lancet. 1991;338(8766):554-557.
84. Baker M, McNicholas A, Garrett N, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J. 2000;19(10):983-990.
85. Deutch S, Labouriau R, Schonheyeder HC, et al. Crowding as a risk factor of meningococcal disease in Danish preschool children: a nationwide population-based case-control study. Scand J Infect Dis. 2004;36(1):20-23.
86. Olcen P, Kjellander J, Danielsson D, Lindquist BL. Epidemiology of Neisseria meningitidis; prevalence and symptoms from the upper respiratory tract in family members to patients with meningococcal disease. Scand J Infect Dis. 1981;13(2):105-109.
87. Hudson PJ, Vogt RL, Heun EM, et al. Evidence for school transmission of Neisseria meningitidis during a Vermont outbreak. Pediatr Infect Dis. 1986;5(2):213-217.
88. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ. 2000;320(7238): 846-849.
89. Brooks R, Woods CW, Benjamin DK Jr, Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis. 2006;43(1):49-54.
90. MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA. 1998;280(19): 1685-1689.
91. Stephens DS. Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics. Trans Am Clin Climatol Assoc. 2011; 122:115-123.
92. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737-743.
93. Harrison LH, Mohan N, Kirkpatrick P. Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev Drug Discov. 2010;9(6):429-430.
94. Pichichero ME. Meningococcal conjugate vaccines. Expert Opin Biol Ther. 2005;5(11):1475-1489.
95. Halperin SA, Gupta A, Jeanfreau R, et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine. 2010;28(50):7865-7872.
96. Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine. 2009;27 Suppl 2:B13-B19.
97. Bishai DM, Champion C, Steele ME, Thompson L. Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health Aff (Millwood). 2011;30(6):1058-1064.
98. Frasch C, Preziosi MP, Laforce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac (TM). Hum Vaccin Immunother. 2012;8(6). [Epub ahead of print.]
99. Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine. 2012;30 Suppl 2:B40-B45.
100. McCoy RD, Vimr ER, Troy FA. CMP-NeuNAc:poly-alpha-2,8-sialosyl sialyltransferase and the biosynthesis of polysialosyl units in neural cell adhesion molecules. J Biol Chem. 1985;260(23):12695-12699.
101. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin. 2007;3(6):290-294.
102. Dolan-Livengood JM, Miller YK, Martin LE, Urwin R, Stephens DS. Genetic basis for nongroupable Neisseria meningitidis. J Infect Dis. 2003;187(10):1616-1628.